

# Antnio Lpez-Beltrn

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2741549/antonio-lopez-beltran-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

550  
papers

16,272  
citations

64  
h-index

105  
g-index

665  
ext. papers

19,017  
ext. citations

5.3  
avg, IF

6.56  
L-index

#	Paper	IF	Citations
550	T1 bladder carcinoma with variant histology: pathological features and clinical significance.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2022</b> , 1	5.1	0
549	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles.. <i>Pathology Research and Practice</i> , <b>2021</b> , 229, 153737	3.4	
548	What's the future in uropathology. <i>Urologia</i> , <b>2021</b> , 88, 265-266	1.2	
547	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2195, 31-47	1.4	1
546	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 543-549	6.7	0
545	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 784-791	6.7	10
544	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , <b>2021</b> , 7, 955-963	5.1	3
543	Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 1506-1520	2.3	7
542	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
541	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	8
540	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 1562-1568	2.3	1
539	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. <i>Modern Pathology</i> , <b>2021</b> , 34, 1384-1391	9.8	3
538	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. <i>Pathology Research and Practice</i> , <b>2021</b> , 219, 153377	3.4	
537	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 1530-1540	2.3	0
536	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
535	RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, <a href="https://doi.org/10.1016/j.urolonc.2020.12.007">https://doi.org/10.1016/j.urolonc.2020.12.007</a> (Low grade papillary intra-urothelial neoplasia). <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 308-309	2.8	
534	Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>Eur Urol</i> 2021;79:489-91. <i>European Urology</i> , <b>2021</b> , 79, e172-e173	10.2	1

533	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2021</b> , 145, 1049-1050	5	
532	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , <b>2021</b> , 4, 331-333	6.7	3
531	Re: Alfonso Gñez de Liañ Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. <i>European Urology</i> , <b>2021</b> , 79, e17-e19	10.2	1
530	Stage T1 bladder cancer: diagnostic criteria and pitfalls. <i>Pathology</i> , <b>2021</b> , 53, 67-85	1.6	5
529	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. <i>European Urology Oncology</i> , <b>2021</b> , 4, 558-569	6.7	3
528	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	51
527	Predicting future cancer burden in the United States by artificial neural networks. <i>Future Oncology</i> , <b>2021</b> , 17, 159-168	3.6	6
526	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 245-251	5.9	3
525	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 1581-1587	2.3	0
524	Molecular pathology of urothelial carcinoma. <i>Human Pathology</i> , <b>2021</b> , 113, 67-83	3.7	4
523	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brödl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology	6.7	
522	Re: Scott Wilkinson, Huihui Ye, Fatima Karzaj, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2021.03.009">https://doi.org/10.1016/j.eururo.2021.03.009</a> : Focus on Intraductal Carcinoma of the Prostate. <i>European Urology</i> , <b>2021</b> , 80, 81-88	10.2	
521	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2195, 49-63	1.4	1
520	Artificial intelligence and prostate cancer: Advances and challenges. <i>Urologia</i> , <b>2021</b> , 3915603211062409	1.2	0
519	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , <b>2020</b> , 9,	7.9	26
518	Urologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. <i>European Urology</i> , <b>2020</b> , 78, 478-481	10.2	8
517	Preimplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. <i>International Journal of Biological Markers</i> , <b>2020</b> , 35, 82-90	2.8	1
516	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	38

515	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. <i>European Urology</i> , <b>2020</b> , 78, 114-116	10.2	3
514	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	2
513	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , <b>2020</b> , 9,	7.9	4
512	Epigenetic modulations and lineage plasticity in advanced prostate cancer. <i>Annals of Oncology</i> , <b>2020</b> , 31, 470-479	10.3	43
511	A Multiplex Test Assessing and in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
510	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2020</b> , 5, 95-100	1.6	1
509	Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. <a href="https://uroweb.org/guideline/prostate-cancer/">https://uroweb.org/guideline/prostate-cancer/</a> . <i>Eur Urol</i> 2019;76:871. <i>European Urology</i> , <b>2020</b> , 77, e122-e127	10.2	
508	Molecular diagnostics in uro-oncology. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 117-121	3.8	1
507	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 111-120	5.1	13
506	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	8
505	Prostatic Acinar Adenocarcinoma, Sarcomatoid Variant. <i>Encyclopedia of Pathology</i> , <b>2020</b> , 319-322	0	
504	Renal Cell Carcinoma, Unclassified. <i>Encyclopedia of Pathology</i> , <b>2020</b> , 342-344	0	
503	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , <b>2020</b> , 21, 1463-1475	3.5	4
502	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , <b>2020</b> , 21, 1664-1671	3	3
501	Staging and Reporting of Renal Cell Carcinomas <b>2020</b> , 423-436		
500	Specimen Handling: Radical and Partial Nephrectomy Specimens <b>2020</b> , 411-422		
499	Bladder Cloacal Extrophy. <i>Encyclopedia of Pathology</i> , <b>2020</b> , 20-22	0	
498	Paratesticular well-differentiated liposarcoma initially diagnosed as fibrous pseudotumour. <i>Indian Journal of Pathology and Microbiology</i> , <b>2020</b> , 63, S53-S55	0.6	0

497	Urothelial Carcinoma, Lymphoepithelioma-Like Type. <i>Encyclopedia of Pathology</i> , <b>2020</b> , 477-479	0	
496	Pathology of the Benign and Malignant Diseases of the Prostate <b>2020</b> , 1-12		
495	Urothelial Carcinoma, Lipid-Rich Type. <i>Encyclopedia of Pathology</i> , <b>2020</b> , 475-477	0	
494	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 231-243	3.8	14
493	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , <b>2020</b> , 12, 1257-1268	3.4	4
492	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 755-763	3.5	7
491	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , <b>2020</b> , 9,	7.9	25
490	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 695-696	3.9	11
489	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>Eur Urol</i> 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology. <i>European Urology</i> , <b>2020</b> , 77, e100-e102	10.2	
488	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , <b>2020</b> , 87, 3-10	1.2	3
487	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 207-217	3.8	4
486	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 255-264	3.8	9
485	Nonneoplastic Disorders of the Urinary Bladder <b>2020</b> , 195-229.e11		1
484	Neoplasms of the Urinary Bladder <b>2020</b> , 230-321.e19		1
483	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 141-150	3.8	9
482	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 3-16	5.1	5
481	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
480	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2019</b> , 475, 735-744	5.1	3

479	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , <b>2019</b> , 11, 1756287218815372	3.2	6
478	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. <i>Modern Pathology</i> , <b>2019</b> , 32, 1666-1674	9.8	4
477	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , <b>2019</b> , 11,	6.6	21
476	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2019</b> , 475, 445-455	5.1	18
475	Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. <i>Apmis</i> , <b>2019</b> , 127, 545-553	3.4	10
474	Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>Eur Urol</i> 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?. <i>European Urology</i> , <b>2019</b> , 76, e69-e72	10.2	5
473	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , <b>2019</b> , 75, 453-467	7.3	1
472	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 228	5.3	14
471	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 178	5.3	10
470	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. <i>Molecular Carcinogenesis</i> , <b>2019</b> , 58, 1272-1278	5	2
469	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , <b>2019</b> , 39, 503-519	3.2	23
468	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	20
467	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>Eur Urol</i> 2019;75:538-40. <i>European Urology</i> , <b>2019</b> , 75, e162-e163	10.2	1
466	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	15
465	Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. <i>World Journal of Urology</i> , <b>2019</b> , 37, 107-114	4	30
464	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. <i>Human Pathology</i> , <b>2019</b> , 93, 6-15	3.7	2
463	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , <b>2019</b> , 11, 1507-1521	3.8	15
462	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, 690	3.2	38

461	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , <b>2019</b> , 20, 305-312	3.5	7
460	Bladder Cloacal Extrophy. <i>Encyclopedia of Pathology</i> , <b>2019</b> , 1-3	0	
459	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2019</b> , 71, 189-190	4.4	1
458	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , <b>2019</b> , 12,	6.6	14
457	?The Prostatic Utricle and Endometrioid Prostate Cancer <b>2019</b> , 123-127		
456	?? Cystic Lesions of the Prostate and Lower Genitourinary Tract versus Female Gynecologic Tract Lesions: Similarities and Differences <b>2019</b> , 128-139		
455	??Ectopic Prostatic Tissue <b>2019</b> , 145-149		
454	?? Prostate and Breast Pathology: Similarities and Differences <b>2019</b> , 155-170		0
453	?? Clear Cell Tumors of the Kidney and the Gynecologic Tract <b>2019</b> , 173-188		
452	??Similarities and Differences in Neuroendocrine Tumors of the Male and Female Genital Tracts and Urinary Tract <b>2019</b> , 233-244		
451	?? Transitional Cell Tumors of the Bladder <b>2019</b> , 254-273		
450	?? Micropapillary Urothelial Carcinoma of the Bladder versus Gynecologic Tract Carcinomas with Micropapillary Features: Similarities and Differences <b>2019</b> , 278-282		
449	?? Pathology of the Female and Male Urethra <b>2019</b> , 285-303		
448	?? Müllerian Lesions of the Bladder: Endometriosis, Endosalpingiosis, Endocervicosis, and Müllerianosis <b>2019</b> , 304-309		
447	??Clear Cell Carcinoma of the Urinary Tract vs. Clear Cell Carcinoma of the Ovary: Similarities and Differences <b>2019</b> , 310-315		
446	??Cystic and Solid Tumors of the Urachus vs. Gynecologic Tract Tumors: Similarities and Differences <b>2019</b> , 316-330		
445	??Secondary Tumors of the Male and Female Genital Tracts and Urinary Tract: Similarities and Differences <b>2019</b> , 397-410		
444	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Journal of Clinical Pathology</i> , <b>2019</b> , 72, 573-578	3.9	3

443	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
442	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , <b>2019</b> , 17, 917-927	2.5	2
441	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, e1-e12	6.7	3
440	Staging of bladder cancer. <i>Histopathology</i> , <b>2019</b> , 74, 112-134	7.3	62
439	Variants and new entities of bladder cancer. <i>Histopathology</i> , <b>2019</b> , 74, 77-96	7.3	64
438	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , <b>2019</b> , 72, 135-139	3.9	17
437	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. <i>J Vasc Interv Radiol</i> 2018;29:589-97. <i>Eur Urol</i> 2018;74:525-6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization?. <i>European Urology</i> , <b>2019</b> , 75, e110-e113	10.2	3
436	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , <b>2019</b> , 8,	7.9	20
435	Histopathologic challenges: The second OPINION issue. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 12-15	3.6	3
434	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , <b>2019</b> , 74, 377-390	7.3	9
433	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. <i>European Urology</i> , <b>2018</b> , 73, 978-980	10.2	1
432	Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. <i>American Journal of Surgical Pathology</i> , <b>2018</b> , 42, e33-e43	6.7	8
431	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 451-460	5.1	7
430	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 64, 11-20	14.4	57
429	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. <i>Future Oncology</i> , <b>2018</b> , 14, 277-290	3.6	14
428	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 467-471	3.9	4
427	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 685-693	3.5	8
426	Iatrogenic pathology of the urinary bladder. <i>Seminars in Diagnostic Pathology</i> , <b>2018</b> , 35, 218-227	4.3	9



425	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2018</b> , 4, 880-888	5.1	18
424	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , <b>2018</b> , 52, 216-227	12.7	11
423	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 221	5.3	18
422	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 2559-2564	3.6	5
421	Re: Isabel Rauscher, Charlotte Döwle, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> <b>2018</b> ;73:656-61. Clinical Significance of Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 68, 80-85	10.2	3
420	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 68, 80-85	14.4	18
419	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2018</b> , 18, 645-655	3.8	13
418	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , <b>2018</b> , 31, 24-38	9.8	206
417	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. <i>Expert Review of Molecular Diagnostics</i> , <b>2018</b> , 18, 1021-1028	3.8	6
416	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 456	5.3	32
415	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 653	5.3	39
414	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 397	5.3	15
413	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 131, 1-6	7	5
412	Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. <i>Apmis</i> , <b>2018</b> , 126, 705-709	3.4	9
411	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. <i>International Journal of Biological Markers</i> , <b>2018</b> , 33, 331-334	2.8	5
410	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , <b>2017</b> , 35, 517-526	4	9
409	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. <i>European Urology</i> , <b>2017</b> , 71, 497-498	10.2	23
408	TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. <i>Future Oncology</i> , <b>2017</b> , 13, 705-714	3.6	18

407	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2017</b> , 21, 401-414	6.4	24
406	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. <i>Future Oncology</i> , <b>2017</b> , 13, 1105-1114	3.6	4
405	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the - fusion gene. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 508-514	3.9	13
404	Lymphoepithelioma-like carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 703-709	5.1	20
403	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. <i>Eur Urol</i> 2017;71:790-807. <i>European Urology</i> , <b>2017</b> , 72, e139-e141	10.2	1
402	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , <b>2017</b> , 17, 781-789	3.8	7
401	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. <i>Pathology Research and Practice</i> , <b>2017</b> , 213, 804-808	3.4	7
400	Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;76:738-9. Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and	10.2	2
399	Considerations for standardizing predictive molecular pathology for cancer prognosis. <i>Expert Review of Molecular Diagnostics</i> , <b>2017</b> , 17, 47-55	3.8	3
398	Iatrogenic changes in the urinary tract. <i>Histopathology</i> , <b>2017</b> , 70, 10-25	7.3	17
397	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , <b>2017</b> , 16, 301-308	0.9	4
396	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2017</b> , 2, 261-274	1.6	1
395	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , <b>2017</b> , 16, 232-240	0.9	2
394	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. <i>European Urology Supplements</i> , <b>2017</b> , 16, 223-231	0.9	3
393	Variants of Bladder Cancer: The Pathologist's Point of View. <i>European Urology Supplements</i> , <b>2017</b> , 16, 210-222	0.9	11
392	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , <b>2017</b> , 16, 309-315	0.9	7
391	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 471, 561-562	5.1	
390	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. <i>Journal of Cancer</i> , <b>2017</b> , 8, 323-331	4.5	15

389	Immunotherapy in genitourinary cancers: where are we going?. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2017</b> , 2, 73-78	1.6	2
388	Pathology Imagebase-a reference image database for standardization of pathology. <i>Histopathology</i> , <b>2017</b> , 71, 677-685	7.3	12
387	Müllerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e1007-e1014	3.3	3
386	Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravesical hyperthermia and chemotherapy (thermochemotherapy). <i>Pathology Research and Practice</i> , <b>2017</b> , 213, 1078-1081	3.4	5
385	Concomitant bladder cancer and prostate cancer: challenges and controversies. <i>Nature Reviews Urology</i> , <b>2017</b> , 14, 620-629	5.5	10
384	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2017</b> , 141, 1460-1461	5	9
383	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , <b>2017</b> , 71, e27-e28	10.2	0
382	TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 814-820	5	5
381	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>European Urology</i> , <b>2017</b> , 71, e73-e75	10.2	6
380	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 305	5.3	17
379	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. <i>Critical Reviews in Oncogenesis</i> , <b>2017</b> , 22, 389-401	1.3	6
378	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , <b>2017</b> , 22, 439-450	1.3	8
377	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , <b>2017</b> , 8, 54096-54105	3.3	16
376	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. <i>Oncotarget</i> , <b>2017</b> , 8, 51522-51529	3.3	6
375	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 723-726	3.5	3
374	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 700-711	3.5	21
373	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 692-699	3.5	7
372	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 712-722	3.5	24

371	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , <b>2017</b> ,	2.8	1
370	Bone Homing and Metastasis <b>2017</b> , 25-32		
369	Prostate cancer grading in 2016. <i>Minerva Urology and Nephrology</i> , <b>2017</b> , 69, 1-4	2.3	
368	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , <b>2016</b> , 69, 186-90	10.2	13
367	Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 469, 321-30	5.1	41
366	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2016</b> , 140, 501-2	5	10
365	Intracardiac leiomyomatosis presenting as an intraoperative consultation. <i>Pathology Research and Practice</i> , <b>2016</b> , 212, 578-81	3.4	1
364	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 433-40	3.5	16
363	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 243-53	2.3	18
362	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. <i>Endocrine Pathology</i> , <b>2016</b> , 27, 123-35	4.2	47
361	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 111-7	4.5	57
360	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 45, 46-57	14.4	117
359	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , <b>2016</b> , 70, e72-4	10.2	5
358	Metabolic Alterations in Renal and Prostate Cancer. <i>Current Drug Metabolism</i> , <b>2016</b> , 17, 150-5	3.5	13
357	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , <b>2016</b> , 17, 750-6		8
356	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , <b>2016</b> , 17, 757-70	3	6
355	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , <b>2016</b> , 17, 777-82		7
354	Urinary Bladder <b>2016</b> , 1681-1735		

353 Renal Pelvis, Ureter, and Urethra **2016**, 1737-1750

352 Emerging Immunotargets in Metastatic Renal Cell Carcinoma. *Current Drug Targets*, **2016**, 17, 771-6 3 12

351 Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. *Advances in Anatomic Pathology*, **2016**, 23, 71-83 5.1 46

350 Spectrum of Cystic Epithelial Tumors of the Prostate: Most Cystadenocarcinomas Are Ductal Type With Intracystic Papillary Pattern. *American Journal of Surgical Pathology*, **2016**, 40, 886-95 6.7 17

349 Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. *Histopathology*, **2016**, 69, 107-13 7.3 40

348 Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. *Apmis*, **2016**, 124, 619-623 3.4 4

347 Intraductal carcinoma of prostate reporting practice: a survey of expert European urologists. *Journal of Clinical Pathology*, **2016**, 69, 852-7 3.9 22

346 Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. *Journal of Clinical Pathology*, **2016**, 69, 547-50 3.9 9

345 Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. *Pathology Research and Practice*, **2016**, 212, 471-4 3.4 2

344 Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. *Eur Urol* 2015;68:542-3. *European Urology*, **2016**, 70, e69-70 10.2

343 Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms **2016**, 275-280

342 Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis **2016**, 165-170

341 Cysts and Epithelial Proliferations of the Testicular Collecting System **2016**, 171-189 1

340 T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II $\beta$ , survivin, and E-cadherin. *Human Pathology*, **2016**, 57, 78-84 3.7 19

339 Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. *Histology and Histopathology*, **2016**, 31, 595-600 1.4 6

338 Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. *Human Pathology*, **2015**, 46, 1040-4 3.7 5

337 BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. *Expert Review of Molecular Diagnostics*, **2015**, 15, 1201-10 3.8 63

336 The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. *Revista Espanola De Patologia*, **2015**, 48, 90-96 1.2

335	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. <i>Future Oncology</i> , <b>2015</b> , 11, 2711-2719	3.6	4
334	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , <b>2015</b> , 34, 765-73	9.6	28
333	Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. <i>Molecular Carcinogenesis</i> , <b>2015</b> , 54, 900-7	5	22
332	Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. <i>European Urology</i> , <b>2015</b> , 67, 85-97	10.2	292
331	Rare Tumors and Tumor-like Conditions in Urological Pathology <b>2015</b> ,		2
330	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , <b>2015</b> , 28, 612-30	9.8	79
329	Re: epithelial-to-mesenchymal transition in renal neoplasms. <i>European Urology</i> , <b>2015</b> , 68, 736-7	10.2	8
328	Urinary bladder xanthoma: a multi-institutional series of 17 cases. <i>Histopathology</i> , <b>2015</b> , 67, 255-61	7.3	5
327	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations. <i>Histopathology</i> , <b>2015</b> , 67, 20-38	7.3	16
326	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 614-22	14.4	18
325	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 303-9	2.8	12
324	The Prostate and Seminal Vesicles <b>2015</b> , 195-310		
323	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , <b>2015</b> , 11, 1381-8	3.6	5
322	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2015</b> , 467, 687-693	5.1	10
321	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 1367-9	3.5	16
320	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , <b>2015</b> , 1, FSO15	2.7	39
319	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , <b>2015</b> , 67, 313-24	7.3	28
318	Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. <i>Current Drug Targets</i> , <b>2015</b> , 16, 96-102	3	5

317	Oncotargets in different renal cancer subtypes. <i>Current Drug Targets</i> , <b>2015</b> , 16, 125-35	3	21
316	Bladder cancer: molecular determinants of personalized therapy. <i>Current Drug Targets</i> , <b>2015</b> , 16, 115-243		14
315	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra <b>2015</b> , 63-194		
314	Renal Tumors and Tumor-Like Conditions <b>2015</b> , 1-61		
313	Prostatic and urothelial metastasis in the same lymph node: a case report. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , <b>2015</b> , 37, 139-43		2
312	Small cell carcinoma of the prostate: molecular basis and clinical implications. <i>Histology and Histopathology</i> , <b>2015</b> , 30, 413-24	1.4	7
311	Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. <i>Human Pathology</i> , <b>2014</b> , 45, 1473-82	3.7	92
310	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , <b>2014</b> , 27, 107-12	9.8	9
309	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. <i>Histopathology</i> , <b>2014</b> , 64, 872-9	7.3	34
308	Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1846, 630-7	11.2	25
307	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. <i>Human Pathology</i> , <b>2014</b> , 45, 2059-62	3.7	7
306	Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. <i>Diagnostic Pathology</i> , <b>2014</b> , 9, 90	3	18
305	Seminal vesicle intraepithelial neoplasia versus basal cell hyperplasia in a seminal vesicle. <i>European Urology</i> , <b>2014</b> , 66, 623-7	10.2	15
304	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. <i>Human Pathology</i> , <b>2014</b> , 45, 745-52	3.7	6
303	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. <i>Pathology</i> , <b>2014</b> , 46, 88-91	1.6	3
302	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. <i>Archivio Italiano Di Urologia Andrologia</i> , <b>2014</b> , 86, 314-8	1.6	2
301	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , <b>2014</b> , 18, 333-42	2.2	35
300	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. <i>Modern Pathology</i> , <b>2014</b> , 27, 1540-8	9.8	14

299	Words of wisdom. Re: Antibody-drug conjugates targeting prostate-specific membrane antigen. <i>European Urology</i> , <b>2014</b> , 66, 1190-3	10.2	5
298	Bladder cancer: Normal cystoscopy, malignant cytology in NMIBC: why biopsy?. <i>Nature Reviews Urology</i> , <b>2014</b> , 11, 550-1	5.5	2
297	The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. <i>Histopathology</i> , <b>2014</b> , 64, 405-11	7.3	43
296	Prostate changes related to therapy: with special reference to hormone therapy. <i>Future Oncology</i> , <b>2014</b> , 10, 1873-86	3.6	1
295	Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , <b>2014</b> , 9, 190	3	6
294	Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, e20-34	6.7	114
293	Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1017-22	6.7	45
292	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , <b>2014</b> , 46, 653-5	1.6	10
291	Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1457-67	6.7	139
290	Primary renal osteosarcoma. <i>American Journal of Clinical Pathology</i> , <b>2014</b> , 141, 747-52	1.9	12
289	Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1251-9	6.7	12
288	Biomarkers in bladder cancer: translational and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 89, 73-111	7	75
287	Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features: a previously unreported pattern of ccRCC with possible clinical significance. <i>European Urology</i> , <b>2014</b> , 66, 806-10	10.2	15
286	The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. <i>PLoS ONE</i> , <b>2014</b> , 9, e95724	3.7	11
285	Role of Pathology in the Multidisciplinary Management of Patients with Prostate Cancer <b>2014</b> , 29-41		
284	Contemporary update on pathology-related issues of adult renal neoplasms. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , <b>2014</b> , 36, 1-8		2
283	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , <b>2013</b> , 36, 37-42	7.2	11
282	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. <i>Human Pathology</i> , <b>2013</b> , 44, 2227-33	3.7	37



281	Reply to Jffne Verine’s letter to the editor Re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. <i>Eur Urol</i> 2013;63:400-1. <i>European Urology</i> , <b>2013</b> , 63, e74-5	10.2	
280	Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. <i>Modern Pathology</i> , <b>2013</b> , 26, 725-32	9.8	68
279	Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma. <i>Diagnostic Pathology</i> , <b>2013</b> , 8, 111	3	9
278	Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 414-26	2.8	30
277	Novel markers of squamous differentiation in the urinary bladder. <i>Human Pathology</i> , <b>2013</b> , 44, 1989-97	3.7	28
276	Pathology of flat bladder lesions with emphasis on putative precursors. <i>Diagnostic Histopathology</i> , <b>2013</b> , 19, 355-365	0.7	2
275	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. <i>Future Oncology</i> , <b>2013</b> , 9, 245-53	3.6	9
274	Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. <i>European Urology</i> , <b>2013</b> , 63, 400-1	10.2	9
273	Reply to Jffne Verine’s letter to the editor Re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. <i>European Urology</i> , <b>2013</b> , 64, e53-4	10.2	
272	Precise morphologic documentation with large-format histology of clinical findings in a bladder cancer patient. <i>European Urology</i> , <b>2013</b> , 64, 519-21	10.2	1
271	Standardization of Gleason grading among 337 European pathologists. <i>Histopathology</i> , <b>2013</b> , 62, 247-56	7.3	107
270	Tumors of the Urinary Bladder <b>2013</b> , 85-100		
269	Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. <i>Human Pathology</i> , <b>2013</b> , 44, 164-72	3.7	61
268	Telomere shortening distinguishes inverted urothelial neoplasms. <i>Histopathology</i> , <b>2013</b> , 62, 595-601	7.3	15
267	Conceptual Evolution in Cancer Biology <b>2013</b> , 77-109		1
266	Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1619-26	6.7	61
265	Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1550-4	6.7	15
264	Somatostatin receptor expression in prostate carcinoma: the urological pathologist’s role in the era of personalised medicine. <i>Pathology</i> , <b>2013</b> , 45, 93-6	1.6	3

263	Laser-assisted microdissection in translational research: theory, technical considerations, and future applications. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2013</b> , 21, 31-47	1.9	56
262	Renal tumors: diagnostic and prognostic biomarkers. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1518-31	6.7	126
261	Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1505-17	6.7	96
260	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 559-62	3.9	9
259	Prostate needle biopsy processing: a survey of laboratory practice across Europe. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 120-3	3.9	18
258	Human papillomavirus is not an etiologic agent of urothelial inverted papillomas. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1223-8	6.7	16
257	Synchronous metastasis from lobular carcinoma and primary carcinoma of the endometrium in a patient after tamoxifen therapy. <i>International Journal of Gynecological Pathology</i> , <b>2013</b> , 32, 66-70	3.2	3
256	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. <i>Histopathology</i> , <b>2013</b> , 63, 767-79	7.3	24
255	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <i>Histopathology</i> , <b>2013</b> , 63, 756-66	7.3	30
254	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. <i>Histopathology</i> , <b>2013</b> , 63, 431-5	7.3	5
253	Pathology of renal cell carcinoma: an update. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , <b>2013</b> , 35, 61-76		9
252	Urothelial dysplasia of the bladder: diagnostic features and clinical significance. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , <b>2013</b> , 35, 121-9		7
251	Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?. <i>European Urology</i> , <b>2012</b> , 61, 424-5	10.2	1
250	KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. <i>Histopathology</i> , <b>2012</b> , 61, 1036-42	7.3	17
249	Utility of whole slide imaging and virtual microscopy in prostate pathology. <i>Apmis</i> , <b>2012</b> , 120, 298-304	3.4	35
248	Unclassified renal cell carcinoma: a report of 56 cases. <i>BJU International</i> , <b>2012</b> , 110, 786-93	5.6	29
247	Lymphocytic vasculitis of the prostate transition zone. <i>BJU International</i> , <b>2012</b> , 110, 1775-80	5.6	6
246	Polyps and Other Nonneoplastic Benign Conditions <b>2012</b> , 71-84		

245 Sarcomatoid Carcinoma (Carcinosarcoma) **2012**, 355-381

244 Congenital Disorders and Pediatric Neoplasms **2012**, 399-422

243 PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. *Journal of Clinical Pathology*, **2012**, 65, 254-6 3.9 35

242 Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uro-pathology. *Journal of Clinical Pathology*, **2012**, 65, 106-13 3.9 32

241 Bladder Cancer: General Features **2012**, 137-159 2

240 Urethral caruncle: clinicopathologic features of 41 cases. *Human Pathology*, **2012**, 43, 1400-4 3.7 44

239 Histologic grading of urothelial carcinoma: a reappraisal. *Human Pathology*, **2012**, 43, 2097-108 3.7 57

238 Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. *Human Pathology*, **2012**, 43, 1875-80 3.7 12

237 Pathology of the Urachus **2012**, 567-579

236 Pathology of Renal Pelvis, Ureter, and Urethra **2012**, 581-608

235 Molecular Determinants of Tumor Recurrence **2012**, 609-622

234 Normal Anatomy and Histology **2012**, 1-16

233 Stage pT1 Urothelial Carcinoma **2012**, 193-215 1

232 Inflammatory and Infectious Conditions **2012**, 17-44 1

231 Neuroendocrine Tumors **2012**, 323-353

230 Benign Epithelial Tumors **2012**, 85-97

229 Urothelial Metaplasia and Hyperplasia **2012**, 45-70 1

228 Grading of Bladder Cancer **2012**, 161-191 2

- 227 Staging of Bladder Cancer **2012**, 217-237
- 226 Flat Urothelial Lesions with Atypia and Urothelial Dysplasia **2012**, 99-112
- 225 Histologic Variants of Urothelial Carcinoma **2012**, 239-281 0
- 224 Adenocarcinoma and Its Putative Precursors and Variants **2012**, 283-203 1
- 223 Urothelial Carcinoma in Situ **2012**, 113-136 1
- 222 Bladder Tumors with Inverted Growth **2012**, 383-398 1
- 221 Lymphoid and Hematopoietic Tumors **2012**, 461-469
- 220 Handling and Reporting of Bladder Specimens **2012**, 525-544 1
- 219 Squamous Cell Carcinoma and Other Squamous Lesions **2012**, 305-321 1
- 218 Soft Tissue Tumors **2012**, 423-459
- 217 Urothelial Carcinoma Following Augmentation Cystoplasty **2012**, 471-484
- 216 Other Rare Tumors **2012**, 485-495
- 215 Secondary Tumors **2012**, 497-505
- 214 Treatment Effects **2012**, 507-523 1
- 213 Diagnostic Immunohistochemistry **2012**, 545-565
- 212 Urine-based Biomarkers **2012**, 655-678
- 211 Tissue-based Biomarkers **2012**, 679-706
- 210 Molecular Pathology of Bladder Cancer **2012**, 707-733

209	Rare Lesions and Tumors of the Urinary Bladder. Selected Issues. <i>Tumori</i> , <b>2012</b> , 98, 274-277	1.7	2
208	Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2012</b> , 25, 67-74	3	7
207	Molecular pathology of lung cancer: key to personalized medicine. <i>Modern Pathology</i> , <b>2012</b> , 25, 347-69	9.8	171
206	The spectrum of morphology in non-neoplastic prostate including cancer mimics. <i>Histopathology</i> , <b>2012</b> , 60, 41-58	7.3	15
205	Staging of prostate cancer. <i>Histopathology</i> , <b>2012</b> , 60, 87-117	7.3	84
204	"No pay, no play" or from "defensive or passive pathology" to "active, clinically oriented pathology". <i>Archives of Pathology and Laboratory Medicine</i> , <b>2012</b> , 136, 1474-5; author reply 1475	5	1
203	Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2012</b> , 136, 410-7	5	88
202	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. <i>Modern Pathology</i> , <b>2012</b> , 25, 1526-33	9.8	63
201	Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 1425-33	6.7	62
200	A contemporary update on pathology reporting for urinary bladder cancer. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2012</b> , 25, 565-71	3	6
199	Rare lesions and tumors of the urinary bladder. Selected issues. <i>Tumori</i> , <b>2012</b> , 98, 274-7	1.7	1
198	<b>2012</b> ,		33
197	Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7 <b>2012</b> , 34, 61-5		3
196	Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. <i>Journal of Molecular Diagnostics</i> , <b>2011</b> , 13, 29-40	5.1	38
195	The clinical and therapeutic implications of cancer stem cell biology. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 1131-43	3.5	24
194	The Gleason grading system: where are we now?. <i>Diagnostic Histopathology</i> , <b>2011</b> , 17, 419-427	0.7	3
193	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. <i>Future Oncology</i> , <b>2011</b> , 7, 519-41	3.6	35
192	KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 540-6	5.8	39

191	Bladder cancer: translating molecular genetic insights into clinical practice. <i>Human Pathology</i> , <b>2011</b> , 42, 455-81	3.7	149
190	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. <i>Human Pathology</i> , <b>2011</b> , 42, 1653-9	3.7	30
189	Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer. Further evidence for field effect in prostatic carcinogenesis. <i>Human Pathology</i> , <b>2011</b> , 42, 1931-6	3.7	12
188	Mixed epithelial and stromal tumors of the kidney: evidence for a single cell of origin with capacity for epithelial and stromal differentiation. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1114-22	6.7	26
187	Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 474-83	6.7	69
186	Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, e34-46	6.7	87
185	Cervical-type squamous metaplasia and myoepithelial cell differentiation in stromal tumor of the prostate. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1752-4	6.7	2
184	Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2011</b> , 24, 489-97	3	6
183	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. <i>BJU International</i> , <b>2011</b> , 107, 532-7	5.6	33
182	Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. <i>BJU International</i> , <b>2011</b> , 108, 1394-401	5.6	40
181	Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. <i>Histopathology</i> , <b>2011</b> , 58, 811-34	7.3	47
180	Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP). <i>Histopathology</i> , <b>2011</b> , 58, 579-85	7.3	25
179	Handling of radical prostatectomy specimens: total embedding with whole mounts, with special reference to the Ancona experience. <i>Histopathology</i> , <b>2011</b> , 59, 1006-10; author reply 1010-1	7.3	12
178	Ectopic prostatic tissue: histogenesis and histopathological characteristics. <i>Histopathology</i> , <b>2011</b> , 58, 750-8	7.3	33
177	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. <i>Diagnostic Pathology</i> , <b>2011</b> , 6, 31	3	7
176	Reply to Kiril Trpkov, Asli Yilmaz—Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports. <i>Eur Urol</i> 2010;58:369-73. <i>European Urology</i> , <b>2011</b> , 59, e7-e8	10.2	
175	Current pathology keys of renal cell carcinoma. <i>European Urology</i> , <b>2011</b> , 60, 634-43	10.2	65
174	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2011</b> , 459, 175-82	5.1	51

173	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. <i>Cellular Oncology (Dordrecht)</i> , <b>2011</b> , 34, 235-43	7.2	5
172	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. <i>Prostate</i> , <b>2011</b> , 71, 1746-51	4.2	20
171	KIT gene mutation and amplification in dysgerminoma of the ovary. <i>Cancer</i> , <b>2011</b> , 117, 2096-103	6.4	60
170	The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 346-54	7.5	75
169	ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. <i>Modern Pathology</i> , <b>2011</b> , 24, 1120-7	9.8	104
168	Nest-like features in bladder, simulating the nested variant of urothelial carcinoma. <i>International Journal of Surgical Pathology</i> , <b>2011</b> , 19, 11-9	1.2	12
167	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 242-7	2.8	3
166	Renal Pelvis, Ureter, and Urethra <b>2011</b> , 1567-1579		
165	Urinary Bladder <b>2011</b> , 1515-1565		
164	Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. <i>Histopathology</i> , <b>2010</b> , 57, 572-9	7.3	14
163	Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. <i>BJU International</i> , <b>2010</b> , 106, 1072-80	5.6	9
162	Genetic profiles in renal tumors. <i>International Journal of Urology</i> , <b>2010</b> , 17, 6-19	2.3	9
161	Clonality and TP53 mutation analysis of focal nodular hyperplasia of the liver. <i>American Journal of Clinical Pathology</i> , <b>2010</b> , 134, 65-70	1.9	7
160	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 843-64	3.5	33
159	Large cell undifferentiated carcinoma of the urinary bladder. <i>Pathology</i> , <b>2010</b> , 42, 364-8	1.6	19
158	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. <i>Modern Pathology</i> , <b>2010</b> , 23, 931-6	9.8	82
157	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. <i>Human Pathology</i> , <b>2010</b> , 41, 155-62	3.7	69
156	Invasive micropapillary urothelial carcinoma of the bladder. <i>Human Pathology</i> , <b>2010</b> , 41, 1159-64	3.7	64

155	The origins of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 865-80	3.5	60
154	Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 371-6	6.7	45
153	Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1367-76	6.7	91
152	Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2010</b> , 23, 511-22	3	19
151	Cyclin D3 gene amplification in bladder carcinoma in situ. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2010</b> , 457, 555-61	5.1	15
150	Reply to Josl. Lopž's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? <i>Eur Urol</i> 2009;56:2707. <i>European Urology</i> , <b>2010</b> , 58, 180-2	10.2	0
149	Words of wisdom. Re: peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. <i>European Urology</i> , <b>2010</b> , 58, 180-2	10.2	2
148	Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. <i>European Urology</i> , <b>2010</b> , 58, 655-68	10.2	73
147	Clonal origin of multifocal hepatocellular carcinoma. <i>Cancer</i> , <b>2010</b> , 116, 4078-85	6.4	15
146	Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. <i>Critical Reviews in Oncology/Hematology</i> , <b>2010</b> , 76, 112-26	7	38
145	Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). <i>Prostate</i> , <b>2010</b> , 70, 1196-200	4.2	37
144	Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Androgen Ablated Prostate Cancer. <i>Analytical Cellular Pathology</i> , <b>2010</b> , 33, 27-36	3.4	6
143	Small cell carcinoma of the urinary bladder. <i>Histology and Histopathology</i> , <b>2010</b> , 25, 217-21	1.4	28
142	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. <i>Analytical Cellular Pathology</i> , <b>2010</b> , 33, 27-36	3.4	4
141	Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2010</b> , 18, 401-10	1.9	48
140	The Pathology of Prostate Cancer <b>2010</b> , 45-83		1
139	Active surveillance for low-risk prostate cancer. <i>Anticancer Research</i> , <b>2010</b> , 30, 3683-92	2.3	4
138	Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2009</b> , 22, 755-62		14



137	Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?. <i>American Journal of Clinical Pathology</i> , <b>2009</b> , 131, 279-83	1.9	50
136	Evidence for common clonal origin of multifocal lung cancers. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 560-70	9.7	118
135	Molecular determinants of tumor recurrence in the urinary bladder. <i>Future Oncology</i> , <b>2009</b> , 5, 843-57	3.6	38
134	Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. <i>European Urology</i> , <b>2009</b> , 56, 105-12	10.2	36
133	Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. <i>European Urology</i> , <b>2009</b> , 55, 402	10.2	0
132	Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. <i>European Urology</i> , <b>2009</b> , 56, 846-7	10.2	2
131	Solitary fibrous tumour of the prostate identified on needle biopsy. <i>European Urology</i> , <b>2009</b> , 56, 564-7	10.2	18
130	Decision support systems for morphology-based diagnosis and prognosis of prostate neoplasms: a methodological approach. <i>Cancer</i> , <b>2009</b> , 115, 3068-77	6.4	9
129	Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. <i>Histopathology</i> , <b>2009</b> , 55, 161-73	7.3	39
128	TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. <i>Modern Pathology</i> , <b>2009</b> , 22, 113-8	9.8	62
127	Staging and reporting of urothelial carcinoma of the urinary bladder. <i>Modern Pathology</i> , <b>2009</b> , 22 Suppl 2, S70-95	9.8	126
126	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. <i>Modern Pathology</i> , <b>2009</b> , 22, 627-32	9.8	40
125	2009 update on the classification of renal epithelial tumors in adults. <i>International Journal of Urology</i> , <b>2009</b> , 16, 432-43	2.3	170
124	Pathological definition and difficulties in assessing positive margins in radical prostatectomy specimens. <i>BJU International</i> , <b>2009</b> , 103, 286-8	5.6	11
123	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. <i>BJU International</i> , <b>2009</b> , 103, 1058-63	5.6	27
122	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. <i>BJU International</i> , <b>2009</b> , 103, 1464-70	5.6	75
121	Secondary neoplasms of the urinary system and male genital organs. <i>BJU International</i> , <b>2009</b> , 104, 770-65.6		54
120	Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. <i>Urology</i> , <b>2009</b> , 74, 385-90	1.6	19

119	Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. <i>Human Pathology</i> , <b>2009</b> , 40, 211-7	3.7	24
118	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. <i>Human Pathology</i> , <b>2009</b> , 40, 10-29	3.7	94
117	Lymphoepithelioma-like carcinoma of the prostate. <i>Human Pathology</i> , <b>2009</b> , 40, 982-7	3.7	18
116	Plasmacytoid urothelial carcinoma of the bladder. <i>Human Pathology</i> , <b>2009</b> , 40, 1023-8	3.7	88
115	Pleomorphic giant cell carcinoma of the urinary bladder. <i>Human Pathology</i> , <b>2009</b> , 40, 1461-6	3.7	36
114	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. <i>European Urology Supplements</i> , <b>2009</b> , 8, 453-457	0.9	21
113	Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2009</b> , 17, 345-50	1.9	25
112	Implications of Cancer Stem Cells for Cancer Therapy <b>2009</b> , 255-262		3
111	The European Network of Uropathology: a novel mechanism for communication between pathologists <b>2009</b> , 31, 90-5		3
110	Pathology of prostate cancer and focal therapy ('male lumpectomy'). <i>Anticancer Research</i> , <b>2009</b> , 29, 5155-61	5.1	18
109	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , <b>2008</b> , 21, 355-62	9.8	31
108	Pathological variants of invasive bladder cancer according to their suggested clinical significance. <i>BJU International</i> , <b>2008</b> , 101, 275-81	5.6	39
107	Rare and unusual histological variants of prostatic carcinoma: clinical significance. <i>BJU International</i> , <b>2008</b> , 102, 1369-74	5.6	39
106	Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. <i>Histopathology</i> , <b>2008</b> , 53, 621-33	7.3	43
105	Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity?. <i>European Urology</i> , <b>2008</b> , 54, 1237-46	10.2	49
104	Editorial comment on: validation of the contemporary epstein criteria for insignificant prostate cancer in European men. <i>European Urology</i> , <b>2008</b> , 54, 1311-2	10.2	
103	Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. <i>European Urology</i> , <b>2008</b> , 54, 843-4	10.2	0
102	Editorial comment on: comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. <i>European Urology</i> , <b>2008</b> , 54, 380-1	10.2	

101	Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?. <i>Journal of Urology</i> , <b>2008</b> , 180, 1235-40	2.5	65
100	Bladder cancer: clinical and pathological profile. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2008</b> , 95-109		64
99	Lymphatic vessel density in radical prostatectomy specimens. <i>Human Pathology</i> , <b>2008</b> , 39, 610-5	3.7	19
98	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. <i>Human Pathology</i> , <b>2008</b> , 39, 954-9	3.7	49
97	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , <b>2008</b> , 25, 232-44	4.3	9
96	Germ cell origin of testicular carcinoid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1393-6	12.9	42
95	Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1947-55	12.9	67
94	Identification of PMF1 methylation in association with bladder cancer progression. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8236-43	12.9	34
93	Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8087-93	12.9	39
92	Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2008</b> , 21, 615-23	3	22
91	Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 146-55	6.7	56
90	Urothelial Dysplasia and Its Mimics <b>2008</b> , 13, 149-153		2
89	Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. <i>Prostate</i> , <b>2008</b> , 68, 919-23	4.2	25
88	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. <i>Cancer</i> , <b>2008</b> , 112, 636-44	6.4	36
87	Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma. <i>Apmis</i> , <b>2008</b> , 116, 934-8	3.4	7
86	Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2008</b> , 1, 475-88	1.4	34
85	Familial Cancer Syndromes <b>2008</b> , 449-466		
84	Neoplasms of the urinary bladder <b>2008</b> , 258-351		11

83	Morphological and molecular profiles and pathways in bladder neoplasms. <i>Anticancer Research</i> , <b>2008</b> , 28, 2893-900	2.3	11
82	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. <i>Modern Pathology</i> , <b>2007</b> , 20, 175-82	9.8	32
81	Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. <i>European Urology</i> , <b>2007</b> , 52, 1682-9	10.2	21
80	Re: Aurlien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? <i>Eur Urol</i> 2006;50:1248-53. <i>European Urology</i> , <b>2007</b> , 52, 294-5	10.2	0
79	Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. <i>Pathology and Oncology Research</i> , <b>2007</b> , 13, 203-8	2.6	9
78	Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2007</b> , 450, 371-8	5.1	33
77	Macrocryosectioning and complete sampling of the prostate in a potential multiorgan donor candidate. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 951-2	3.9	4
76	Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 332-5	3.9	51
75	Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 443-6	3.9	12
74	alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. <i>American Journal of Clinical Pathology</i> , <b>2007</b> , 128, 657-66	1.9	24
73	Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 953-7	12.9	66
72	Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6232-6	12.9	48
71	Expression of OCT4 transcription factor in cutaneous neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2007</b> , 15, 359-62	1.9	8
70	Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 1861-7	6.7	72
69	Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2007</b> , 15, 8-18	1.9	40
68	Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. <i>Nature Reviews Urology</i> , <b>2007</b> , 4, 321-32		65
67	BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. <i>Cancer Letters</i> , <b>2007</b> , 250, 292-9	9.9	34
66	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. <i>Human Pathology</i> , <b>2007</b> , 38, 1207-11	3.7	61

65	Soft tissue tumors of the urinary bladder Part II: malignant neoplasms. <i>Human Pathology</i> , <b>2007</b> , 38, 963-977	3.7	69
64	Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. <i>Human Pathology</i> , <b>2007</b> , 38, 807-23	3.7	80
63	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. <i>Current Diagnostic Pathology</i> , <b>2007</b> , 13, 490-498		4
62	Pathology of tumors of the renal pelvis and ureter and the urethra <b>2007</b> , 235-242		1
61	2005 update on pathology of prostate biopsies with cancer. <i>European Urology</i> , <b>2006</b> , 49, 441-7	10.2	12
60	2004 WHO classification of the renal tumors of the adults. <i>European Urology</i> , <b>2006</b> , 49, 798-805	10.2	608
59	Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy"). <i>European Urology</i> , <b>2006</b> , 50, 666-74	10.2	55
58	Natural history of urothelial inverted papilloma. <i>Cancer</i> , <b>2006</b> , 107, 2622-7	6.4	68
57	Multilocular Cystic Renal Cell Carcinoma. <i>American Journal of Clinical Pathology</i> , <b>2006</b> , 125, 217-222	1.9	124
56	Apoptotic and proliferation indexes in primary superficial bladder tumors. <i>Cancer Letters</i> , <b>2006</b> , 242, 266-72	9.9	17
55	Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. <i>Human Pathology</i> , <b>2006</b> , 37, 1371-88	3.7	172
54	A working group classification of focal prostate atrophy lesions. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1281-91	6.7	97
53	Prostate carcinoma I: prognostic factors in radical prostatectomy specimens and pelvic lymph nodes. <i>BJU International</i> , <b>2006</b> , 97, 485-91	5.6	25
52	Prostate carcinoma II: prognostic factors in prostate needle biopsies. <i>BJU International</i> , <b>2006</b> , 97, 492-7	5.6	30
51	The pathology of bladder cancer: An update on selected issues. <i>BJU International</i> , <b>2006</b> , 98, 1161-5	5.6	13
50	Inverted papilloma of the urinary bladder: a molecular genetic appraisal. <i>Modern Pathology</i> , <b>2006</b> , 19, 1289-94	9.8	54
49	Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. <i>Modern Pathology</i> , <b>2006</b> , 19, 1395-401	9.8	73
48	Current practice of Gleason grading of prostate carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 448, 111-8	5.1	42

47	Histopathology reporting of prostate needle biopsies. 2005 update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 1-13	5.1	13
46	The dilemma of multiorgan donors with high serum PSA--a pathologist's proposal. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 273-6	5.1	6
45	Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential. <i>American Journal of Clinical Pathology</i> , <b>2006</b> , 125, 217-22	1.9	56
44	Urinary Bladder <b>2006</b> , 1175-1218		
43	The 2004 WHO classification of bladder tumors: a summary and commentary. <i>International Journal of Surgical Pathology</i> , <b>2005</b> , 13, 143-53	1.2	176
42	Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. <i>Human Pathology</i> , <b>2005</b> , 36, 718-23	3.7	120
41	Association of human herpesvirus type 6 DNA with human bladder cancer. <i>Cancer Letters</i> , <b>2005</b> , 230, 20-4	9.9	11
40	Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. <i>American Journal of Pathology</i> , <b>2005</b> , 166, 1533-9	5.8	151
39	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1228-42	6.7	1909
38	Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. <i>BJU International</i> , <b>2005</b> , 95, 1146-52	5.6	91
37	c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. <i>Modern Pathology</i> , <b>2005</b> , 18, 320-3	9.8	63
36	Clonal origin of lymph node metastases in bladder carcinoma. <i>Cancer</i> , <b>2005</b> , 104, 1901-10	6.4	40
35	Molecular evidence supporting field effect in urothelial carcinogenesis. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6512-9	12.9	134
34	Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 7226-33	12.9	84
33	Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype. <i>International Journal of Surgical Pathology</i> , <b>2005</b> , 13, 167-73	1.2	14
32	Pleomorphic giant cell carcinoma of the prostate. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2005</b> , 129, 683-5	5	33
31	Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features <b>2005</b> , 27, 143-51		3
30	P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. <i>Anticancer Research</i> , <b>2005</b> , 25, 2001-4	2.3	15

29	Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors. <i>American Journal of Clinical Pathology</i> , <b>2004</b> , 122, 444-452	1.9	68
28	Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. <i>European Urology</i> , <b>2004</b> , 45, 257-66	10.2	87
27	Non-invasive urothelial neoplasms: according to the most recent WHO classification. <i>European Urology</i> , <b>2004</b> , 46, 170-6	10.2	123
26	Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uro pathology and the Uro pathology Working Group. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2004</b> , 445, 103-10	5.1	21
25	Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. <i>Cancer</i> , <b>2004</b> , 101, 957-62	6.4	230
24	Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. <i>American Journal of Clinical Pathology</i> , <b>2004</b> , 122, 444-52	1.9	31
23	Inflammatory myofibroblastic tumors of the kidney: a clinicopathologic and immunohistochemical study of 12 cases. <i>American Journal of Surgical Pathology</i> , <b>2003</b> , 27, 658-66	6.7	78
22	Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. <i>Pathology</i> , <b>2003</b> , 35, 484-91	1.6	52
21	Sclerosing adenosis of the prostate. Histologic features in needle biopsy specimens. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2003</b> , 127, e14-6	5	20
20	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2002</b> , 440, 3-11	5.1	87
19	Evaluation of prognostic factors in radical prostatectomy specimens with cancer. <i>Urologia Internationalis</i> , <b>2002</b> , 68, 209-15	1.9	13
18	Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2001</b> , 438, 552-7	5.1	91
17	Bladder treatment. Immunotherapy and chemotherapy. <i>Urologic Clinics of North America</i> , <b>1999</b> , 26, 535-549	2.9	20
16	Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis. <i>The Anatomical Record</i> , <b>1998</b> , 252, 17-33		38
15	Prostatic adenocarcinoma with glomeruloid features. <i>Human Pathology</i> , <b>1998</b> , 29, 543-6	3.7	34
14	Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. <i>Urology</i> , <b>1997</b> , 50, 427-31	1.6	86
13	Virilizing mature ovarian cystic teratomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>1997</b> , 431, 149-51	5.1	18
12	Ultrastructure of prostatic intraepithelial neoplasia. <i>Prostate</i> , <b>1997</b> , 33, 32-7	4.2	17

11	Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. <i>American Journal of Surgical Pathology</i> , <b>1997</b> , 21, 931-5	6.7	51
10	Lipomatous hypertrophy of the cardiac interatrial septum. <i>American Journal of Forensic Medicine and Pathology</i> , <b>1997</b> , 18, 206-7	1	
9	Vasculitis Involving the Prostate <b>1996</b> , 1, 70-73		3
8	Molecular biology of prostatic intraepithelial neoplasia. <i>Prostate</i> , <b>1996</b> , 29, 117-34	4.2	148
7	Assessment of prostate carcinoma in core needle biopsy--definition of minimal criteria for the diagnosis of cancer in biopsy material. <i>Cancer</i> , <b>1996</b> , 78, 376-81	6.4	76
6	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy--Definition of minimal criteria for the diagnosis of cancer in biopsy material <b>1996</b> , 78, 376		3
5	Inflammatory pseudotumor of the urinary bladder. A clinicopathological analysis of two cases. <i>Urologia Internationalis</i> , <b>1995</b> , 55, 173-6	1.9	21
4	Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. <i>Cellular Immunology</i> , <b>1994</b> , 158, 208-17	4.4	37
3	Prognostic factors in survival of bladder cancer. <i>Cancer</i> , <b>1992</b> , 70, 799-807	6.4	20
2	Evolution of extramedullary plasmacytoma in a patient with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , <b>1990</b> , 33, 150-1		8
1	T-zone histiocytes and recurrence of papillary urothelial bladder carcinoma. <i>Urologia Internationalis</i> , <b>1989</b> , 44, 205-9	1.9	14